1173C>T Polymorphism in VKORC1 Modulates the Required Warfarin Dose

作者: K. Kosaki , C. Yamaghishi , R. Sato , H. Semejima , H. Fuijita

DOI: 10.1007/S00246-005-1150-X

关键词:

摘要: The response to warfarin is highly variable among individuals and such variability likely have some genetic basis. We evaluted the effect of VKORC1 polymorphisms on Japanese, taking advantage its unique population structure in which CYP2C9 *2 *3 alleles are relatively rare. Thirty-one patients (12–34 years old; median, 22) were recruited from a pediatric cardiology clinic. Genotyping C>T polymorphism at position 1173 intron 1 revealed that 26 (84%) T/T homozygotes nucleotide 1173, whereas 5 (16%) C/T heterozygotes. Complete linkage disequilibrium was observed between 1173C > T another polymorphism, 3730G A, 3′ untranslated region. heterozyogtes tended require more than homozygotes, when adjusted for international normalized ratio (p = 0.003). Both A be inert functional standpoint. Rather, based complete polymorphisms, we suspect actual change defines relative resistance may present proximity these two polymorphisms.

参考文章(14)
Michael J. Stubbins, Lorna W. Harries, Gillian Smith, Michael H. Tarbit, C Roland Wolf, Genetic analysis of the human cytochrome P450 CYP2C9 locus. Pharmacogenetics. ,vol. 6, pp. 429- 439 ,(1996) , 10.1097/00008571-199610000-00007
Allan E. Rettie, Larry C. Wienkers, Frank J. Gonzalez, William F. Trager, Kenneth R. Korzekwa, Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics. ,vol. 4, pp. 39- 42 ,(1994) , 10.1097/00008571-199402000-00005
Simone Rost, Andreas Fregin, Vytautas Ivaskevicius, Ernst Conzelmann, Konstanze Hörtnagel, Hans-Joachim Pelz, Knut Lappegard, Erhard Seifried, Inge Scharrer, Edward G. D. Tuddenham, Clemens R. Müller, Tim M. Strom, Johannes Oldenburg, Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2 Nature. ,vol. 427, pp. 537- 541 ,(2004) , 10.1038/NATURE02214
Stephan D Fihn, Catherine M Callahan, Donald C Martin, Mary B McDonell, Jorja G Henikoff, Richard H White, The Risk for and Severity of Bleeding Complications in Elderly Patients Treated with Warfarin Annals of Internal Medicine. ,vol. 124, pp. 970- 979 ,(1996) , 10.7326/0003-4819-124-11-199606010-00004
Daniel J. Steward, Robert L. Haining, Kirk R. Henne, George Davis, Thomas H. Rushmore, William F. Trager, Allan E. Rettie, Genetic association between sensitivity to warfarin and expression of CYP2C9*3 Pharmacogenetics. ,vol. 7, pp. 361- 367 ,(1997) , 10.1097/00008571-199710000-00004
Dominic Harrington, Sarah Underwood, Colin Morse, Martin Shearer, Edward Tuddenham, Andrew Mumford, Pharmacodynamic resistance to warfarin associated with a Val66Met substitution in vitamin K epoxide reductase complex subunit 1. Thrombosis and Haemostasis. ,vol. 93, pp. 23- 26 ,(2004) , 10.1160/TH04-08-0540
Harumi Takahashi, Ichiro Ieiri, Grant R. Wilkinson, Gail Mayo, Toshitaka Kashima, Sosuke Kimura, Kenji Otsubo, Hirotoshi Echizen, 5′-Flanking region polymorphisms of CYP2C9 and their relationship to S-warfarin metabolism in white and Japanese patients Blood. ,vol. 103, pp. 3055- 3057 ,(2004) , 10.1182/BLOOD-2003-07-2521
A H James, R P Britt, C L Raskino, S G Thompson, Factors affecting the maintenance dose of warfarin. Journal of Clinical Pathology. ,vol. 45, pp. 704- 706 ,(1992) , 10.1136/JCP.45.8.704
Rou-Yee Chenhsu, Shu-Chiung Chiang, Mei-Huei Chou, Ming-Fang Lin, Long-Term Treatment with Warfarin in Chinese Population Annals of Pharmacotherapy. ,vol. 34, pp. 1395- 1401 ,(2000) , 10.1345/APH.19289